Last updated on July 2019

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study


Brief description of study

The purpose of this study is to allow continued use of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development & Medical Affairs (CD&MA) study and are benefiting from the treatment as judged by the investigator

Clinical Study Identifier: NCT01735955

Find a site near you

Start Over

Novartis Investigative Site

Suwon, Korea, Republic of
  Connect »

Novartis Investigative Site

Seoul, Korea, Republic of
  Connect »

Novartis Investigative Site

Cambridge, United Kingdom
  Connect »

Novartis Investigative Site

Manchester, United Kingdom
  Connect »

Novartis Investigative Site

Newcastle upon Tyne, United Kingdom
  Connect »

Novartis Investigative Site

Moscow, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.